8-K: BioMarin Reports Strong 2025 Growth, Acquires Amicus

BioMarin Pharmaceutical Inc. announced robust fourth quarter and full-year 2025 financial results, including double-digit revenue growth, and confirmed the acquisition of Amicus Therapeutics to diversify and accelerate future revenues.

Summary

• Full-year 2025 Total Revenues increased 13% year-over-year to $3.2 billion.
• Fourth Quarter 2025 Total Revenues increased 17% year-over-year to $875 million.
• VOXZOGO generated 26% year-over-year revenue growth for full-year 2025, reaching $927 million, with approximately 73% of revenue from markets outside the U.S.
• Enzyme Therapies (ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ, VIMIZIM) full-year 2025 revenue advanced 9% year-over-year to $2.105 billion, led by 22% growth from PALYNZIQ.
• BioMarin announced a definitive agreement to acquire Amicus Therapeutics in December 2025, expected to close in Q2 2026, adding Galafold for Fabry Disease and Pombiliti + Opfolda for Pompe Disease.
• The company made a strategic decision to voluntarily withdraw ROCTAVIAN from the market after being unable to identify a qualified buyer, resulting in approximately $240 million in charges during Q4 2025.
• GAAP Net Loss for Q4 2025 was $47 million, compared to GAAP Net Income of $125 million for Q4 2024, primarily due to ROCTAVIAN withdrawal charges.
• Full-year 2025 GAAP Net Income was $349 million, an 18% decrease from $427 million in 2024.
• Full-year 2025 Non-GAAP Income was $614 million, a 10% decrease from $686 million in 2024.
• Operating cash flows totaled $828 million for the full year 2025, with total cash and investments at approximately $2 billion at year-end.
• BioMarin secured approximately $3.7 billion of non-convertible debt with favorable pricing to support the Amicus acquisition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, balancing strong underlying product growth and a strategic acquisition with the significant financial impact of the ROCTAVIAN withdrawal. The future outlook and pipeline progress are encouraging.

Positives

• Achieved double-digit topline growth with full-year 2025 total revenues increasing 13% year-over-year to $3.2 billion.
• VOXZOGO demonstrated strong growth, with 26% year-over-year revenue increase for full-year 2025, driven by deeper market penetration and increasing demand globally.
• Enzyme Therapies revenue grew 9% year-over-year for full-year 2025, supported by sustained high market penetration and patient adherence, with PALYNZIQ growing 22%.
• The acquisition of Amicus Therapeutics is expected to significantly accelerate and diversify BioMarin's revenue growth through the next decade by adding high-growth products Galafold and Pombiliti + Opfolda.
• Generated strong operating cash flows totaling $828 million for the full year 2025, contributing to approximately $2 billion in cash and investments at year-end.
• Advanced multiple pipeline medicines, including BMN 333 (long-acting CNP) with Phase 1 PK data exceeding targeted free CNP exposure levels, and positive Phase 3 PEGASUS study data for PALYNZIQ in adolescents.
• Secured financing of approximately $3.7 billion of non-convertible debt for the Amicus acquisition with strong demand and favorable pricing.
• Provided 2026 full-year financial guidance (excluding Amicus contribution) projecting total revenues of $3.325 billion to $3.425 billion and Non-GAAP Diluted EPS of $4.95 to $5.15, indicating continued growth.

Negatives

• Reported a GAAP Net Loss of $47 million for the fourth quarter of 2025, compared to GAAP Net Income of $125 million in the same period of 2024.
• Full-year 2025 GAAP Net Income decreased 18% to $349 million from $427 million in 2024.
• Full-year 2025 Non-GAAP Income decreased 10% to $614 million from $686 million in 2024.
• Voluntarily withdrew ROCTAVIAN from the market after being unable to identify a qualified buyer, resulting in approximately $240 million in charges during Q4 2025, including a $119 million inventory write-off and $118 million in long-lived asset impairments.
• KUVAN revenue decreased 17% year-over-year for full-year 2025 to $100 million.

Risks

• BioMarin's success in the commercialization of its commercial products.
• BioMarin's ability to consummate and realize the anticipated benefits of any acquisitions, specifically the Amicus Therapeutics acquisition.
• Impacts of macroeconomic and other external factors on BioMarin's operations.
• Regulatory uncertainty, including the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency, the European Commission, and other regulatory authorities.
• The impact of new or increased tariffs, other trade protection measures, and escalating trade tensions.
• Results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials.
• BioMarin's ability to successfully manufacture its commercial products and product candidates.
• The market for each of BioMarin's products.
• BioMarin's ability to meet product demand.
• Actual sales of BioMarin's commercial products differing from expectations.

Future Outlook

BioMarin expects to build on its 2025 success with another year of strong financial performance and momentum across the business in 2026. The company anticipates full-year 2026 total revenues between $3.325 billion and $3.425 billion and Non-GAAP Diluted EPS between $4.95 and $5.15, excluding any post-close contribution from the Amicus acquisition. Significant pipeline catalysts are expected throughout the year, including three major data read-outs to support regulatory approvals, two age label expansions, and the advancement of multiple clinical programs. The Amicus acquisition, expected to close in Q2 2026, is projected to further strengthen revenue growth through the next decade.

Management Comments

• "In 2025, operational excellence led to strengthening financial results, including double-digit topline growth, strong profitability and increasing cash flow." Alexander Hardy, President and Chief Executive Officer of BioMarin.
• "The Amicus transaction, which is expected to close in the second quarter, represents a compelling opportunity to reach more patients around the world and further strengthen our revenue growth through the next decade." Alexander Hardy.
• "We expect to build on this success in 2026, with another year of strong financial performance and momentum across the business." Alexander Hardy.
• "We look forward to adding Galafold and Pombiliti + Opfolda to our growing commercial enzyme therapies business, and to continued strong growth from VOXZOGO." Alexander Hardy.
• "We are energized by what lies ahead this year and intend to deliver again on an ambitious set of priorities, demonstrating our dedication to innovation and sustained growth in ways that we believe will benefit patients, employees, and shareholders." Alexander Hardy.

Industry Context

StockSavvy.ai notes that BioMarin's acquisition of Amicus Therapeutics aligns with a broader trend in the biotechnology sector where established rare disease companies seek to expand their portfolios and market reach through strategic M&A, especially for assets with strong growth potential like Galafold and Pombiliti + Opfolda. The focus on enzyme therapies and gene therapies for genetically defined conditions positions BioMarin within a high-growth, specialized segment of the pharmaceutical industry. The withdrawal of ROCTAVIAN highlights the inherent risks and challenges in commercializing novel gene therapies, even after regulatory approval.

Comparison to Industry Standards

• BioMarin's 13% year-over-year revenue growth for full-year 2025 is strong, particularly for a company of its size in the rare disease space, often exceeding the average growth rates of mature pharmaceutical companies.
• VOXZOGO's 26% year-over-year growth demonstrates exceptional market penetration and demand, comparable to the rapid uptake seen in other successful orphan drugs in their early commercial phases.
• The strategic acquisition of Amicus Therapeutics, with its Fabry and Pompe disease assets, positions BioMarin to compete more directly with companies like Sanofi (which markets Fabrazyme for Fabry and Myozyme/Lumizyme for Pompe) and Takeda (with Replagal for Fabry), aiming to capture a larger share of these multi-billion dollar markets.
• The decision to withdraw ROCTAVIAN, a gene therapy for hemophilia A, contrasts with the continued commercialization efforts by competitors like Pfizer and Sangamo (with giroctocogene fitelparvovec) or Roche/Genentech (with Hemlibra, a non-gene therapy but a major competitor in hemophilia A), highlighting the significant commercial hurdles and patient access challenges faced by some gene therapies despite clinical efficacy.

Stakeholder Impact

• Shareholders: Potential for increased long-term revenue growth and diversification from the Amicus acquisition, but short-term financial performance was impacted by the ROCTAVIAN withdrawal. Future pipeline catalysts offer growth potential.
• Patients: Continued access to BioMarin's existing enzyme therapies and VOXZOGO. Potential for new treatments for achondroplasia (BMN 333), hypochondroplasia, idiopathic short stature, Noonan syndrome, Turner syndrome, SHOX deficiency (VOXZOGO), PKU (PALYNZIQ label expansion), Duchenne muscular dystrophy (BMN 351), ENPP1 deficiency (BMN 401). Patients with Fabry and Pompe disease will benefit from the acquisition of Galafold and Pombiliti + Opfolda. ROCTAVIAN patients will no longer have access to the therapy from BioMarin.
• Employees: Continued investment in innovation and future growth suggests stability and potential for new opportunities, especially with the integration of Amicus Therapeutics.
• Creditors: Secured $3.7 billion in non-convertible debt for the Amicus acquisition, indicating increased leverage but also confidence in future cash flows.

Next Steps

• Host a conference call and webcast to discuss fourth quarter 2025 financial results on February 23, 2026, at 4:30 p.m. ET.
• Anticipated closing of Amicus Therapeutics acquisition in Q2 2026, subject to regulatory clearances, stockholder approval, and other customary closing conditions.
• Expect Phase 3 hypochondroplasia data for VOXZOGO in 1H 2026, followed by regulatory submissions in 2H 2026.
• File U.S. supplemental new drug application (sNDA) for full approval of VOXZOGO in achondroplasia in Q2 2026.
• Advance Phase 2 studies for VOXZOGO in idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency.
• Initiate registration-enabling Phase 2/3 study for BMN 333 (long-acting CNP) in achondroplasia in 1H 2026.
• U.S. PDUFA date for PALYNZIQ adolescent label expansion is February 28, 2026, with EU approval expected in 2026.
• Expect BMN 401 Phase 3 topline data in 1 to 12 year-old population with ENPP1 deficiency in 1H 2026, with global regulatory submissions in 2H 2026 and potential first-in-disease launch in 2027.
• Present BMN 351 Phase 1/2 data for 6 mg/kg and 9 mg/kg cohorts at the Muscular Dystrophy Association (MDA) Clinical & Scientific Congress (March 8-11, 2026).
• Expect topline data readout from BMN 351 12 mg/kg dose cohort in 2H 2026.
• Anticipate adolescent label expansion for Pombiliti + Opfolda in 2H 2026.

Key Dates

Recommendation

While BioMarin demonstrated strong underlying product growth, particularly with VOXZOGO and its enzyme therapies, and made a strategic acquisition of Amicus Therapeutics to bolster its future revenue pipeline, the significant financial impact from the voluntary withdrawal of ROCTAVIAN introduces a notable headwind. The 2026 guidance, excluding Amicus, suggests continued growth, but the immediate GAAP net loss and reduced non-GAAP income for 2025 reflect a mixed financial picture. Investors should hold to observe the successful integration of Amicus and the execution of the pipeline catalysts, as these will be crucial for long-term value creation.

Keywords

BioMarin, BMRN, Rare Disease, Biotechnology, Achondroplasia, Fabry Disease, Pompe Disease, PKU, Duchenne Muscular Dystrophy, VOXZOGO, PALYNZIQ, Galafold, Pombiliti, Opfolda, Amicus Therapeutics, Earnings, Financial Results, SEC Filing, 8-K